However, it remains unclear whether the better outcome of the disease is related to the genetic changes, that is, IRF4 rearrangement, or other clinical and pathologic features of this tumor, such as the young age of the patients, relatively early‐stage disease at presentation, and a predominant GCB‐derived tumor phenotype, which are all well‐known factors associated with a better prognosis. This evidence concerns the gene IRF4 and neoplasm.